Anti-recurrence Treatment of Postresection on HCC Patients With MVI Presence and Over-expression of ASPH
NCT ID: NCT02587884
Last Updated: 2016-03-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
180 participants
INTERVENTIONAL
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group TACE
Patients will treated with TACE after resection.
TACE
Patients will treated by TACE in 4 or 8 weeks after operation.
Group Control
Patients will treated without TACE after resection.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TACE
Patients will treated by TACE in 4 or 8 weeks after operation.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Pathological evidence of HCC
3. Confirm presence of MVI and over-expression of ASPH after opreation
4. Within Milan criteria
5. Estimate tumor can gain treatment of curing operation
6. No evidence for extrahepatic metestasis
7. liver function ：Child-Pugh A/B
Exclusion Criteria
2. Impossible to come to our hospital for physical examination regularly
3. Patients with apparent cardiac, pulmonary, cerebral and renal dysfunction
4. Female with pregnancy or during the lactation period
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eastern Hepatobiliary Surgery Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
ShenFeng
vice president of the Eastern Hepatobiliary Surgery Hospital Affiliation: Eastern Hepatobiliary Surgery Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shen Feng, MD
Role: PRINCIPAL_INVESTIGATOR
Eastern Hepatobiliary Surgery Hospital, Second Military Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eastern hepatobilliary surgery hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Feng Shen, MD
Role: primary
Yong Xia, Doctor
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EHBHKY2015-01-024
Identifier Type: -
Identifier Source: org_study_id